More importantly, we provide the first evidence that oral administration of azilsartan, a newly developed AT1R blocker approved by the U.S. Food and Drug Administration (FDA) for hypertension treatment [11], rescues the apoptosis of dopaminergic neurons and relieves the characteristic parkinsonian symptoms in a PD model induced by rotenone. The gene discussed is AGTR1; the disease is hypertensive disorder.